Uveal Melanoma Treatment: An Update

Uveal melanoma is a rare malignancy arising from uveal tract melanocytes. Definitive treatment options for primary disease include plaque brachytherapy, proton beam radiotherapy and enucleation, which provide high rates of local control, but are associated with vision impairment, reduced quality of life and unsatisfactorily high rates of metastatic relapse. In the metastatic setting, average life expectancy remains less than 2 years, despite the availability of immune checkpoint inhibitors and the more recent arrival of the T cell‐engaging agent, tebentafusp. Here, we provide an update regarding the current treatment of uveal melanoma, and discuss the potential roles of novel targeted therapies, immunotherapy and neoadjuvant therapy in shaping future management.